Sponge like microparticles for drug delivery and cosmeto-textile use: Formulation and human skin penetration

Affiliation auteurs!!!! Error affiliation !!!!
TitreSponge like microparticles for drug delivery and cosmeto-textile use: Formulation and human skin penetration
Type de publicationJournal Article
Year of Publication2017
AuteursZafar N, Robin S, Viennet C, Humbert P, Valour JPierre, Agusti G, Fessi H, Elaissari A
JournalINTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume532
Pagination623-634
Date PublishedOCT 30
Type of ArticleArticle
ISSN0378-5173
Mots-clésalpha-tocopherol (Vit. E), Anti-hair growth, Anti-inflammation, Antioxidant, Cosmetology, Double emulsion-solvent evaporation, Eudragit (R) RS100, Hydroxypropyl-beta-cyclodextrin (HP beta CD), Indomethacin (IMC), Lauryl Isoquinolinium Bromide (LIB), Zeta CAD
Résumé

This unique work is targeted to achieve three main goals: i) to enhance the aqueous solubility of three specifically selected hydrophobic active agents, ii) to prepare such polymeric biodegradable microparticles which can encapsulate actives-cyclodextrin complexes and iii) to functionalize a polyamide base textile with active loaded microparticles and active-cyclodextrin loaded microparticles. To achieve this objective, biodegradable cationic microparticles were prepared via double emulsion solvent evaporation process and were loaded with hydroxypropyl-beta-cyclodextrin based complexes of Indomethacin, a-tocopheroland Lauryl Isoquinolinium Bromide during the formulation process. Inclusion complex based particles were evaluated for their morphology, size distribution, zeta potential, skin penetration aptitude and adsorption onto a selected textile. It was observed that active-cyclodextrin complex encapsulation do not affect the morphology, size and zeta potential of the microparticles as well as adsorption of the microparticles onto textile remains unaltered. However such active-cyclodextrin complex encapsulated particles provided the enhancement in the aqueous solubility of hydrophobic agents and also provided prolonged release formulations.

DOI10.1016/j.ijpharm.2017.08.122